H.C. Wainwright reiterates Buy rating on Nuvation Bio stock at $10 price target

Investing.com - H.C. Wainwright has maintained its Buy rating and $10.00 price target on Nuvation Bio Inc (NYSE:NUVB), citing potential market opportunities for the company’s cancer drug IBTROZI. The stock has shown strong momentum, gaining over 60% in the past six months, with InvestingPro data showing analyst consensus remains firmly bullish with price targets ranging from $6 to $10.

The research firm noted that Nuvation recently initiated a new Phase 3 trial called TRUST-IV for IBTROZI (taletrectinib) as an adjuvant therapy for ROS1-fusion positive Stage IB, II, and IIIA non-small cell lung cancer (NSCLC) patients following complete tumor resection.

The primary endpoint of the trial is disease-free survival, with the annual U.S. incidence for this specific patient population estimated at approximately 1,500 patients, compared to roughly 2,500 newly-diagnosed metastatic ROS1+ NSCLC patients expected to receive front-line therapy in 2025.

H.C. Wainwright highlighted that no other ROS1-targeted agent is currently being evaluated in this setting, positioning the front-line ROS1+ NSCLC market as a significant untapped opportunity for IBTROZI.

The firm also noted that its current financial models do not include risk-adjusted revenues for IBTROZI in this patient population, suggesting potential upside to its sales forecasts if the drug succeeds in this indication. With over 10 additional key insights available on InvestingPro, including detailed financial health metrics and growth projections, subscribers can access comprehensive analysis to better evaluate NUVB’s potential.

In other recent news, Nuvation Bio Inc. reported its second-quarter earnings for 2025, aligning with forecasts by posting an earnings per share (EPS) of -$0.17. The company notably exceeded revenue expectations, reporting $4.8 million compared to the anticipated $416,670. These financial results highlight a significant revenue performance for the quarter. Additionally, Nuvation Bio announced that Japan’s Ministry of Health, Labour and Welfare has approved its drug IBTROZI for the treatment of ROS1-positive non-small cell lung cancer. This approval allows Nippon Kayaku to commercialize the drug in Japan under an exclusive license agreement established in 2023. The Japanese approval follows similar clearances in the United States and China earlier this year. These developments mark important milestones for Nuvation Bio’s expansion in the global pharmaceutical market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.